JP7722991B2 - 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法 - Google Patents

抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法

Info

Publication number
JP7722991B2
JP7722991B2 JP2022529066A JP2022529066A JP7722991B2 JP 7722991 B2 JP7722991 B2 JP 7722991B2 JP 2022529066 A JP2022529066 A JP 2022529066A JP 2022529066 A JP2022529066 A JP 2022529066A JP 7722991 B2 JP7722991 B2 JP 7722991B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
patient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022529066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502398A5 (https=
JPWO2021101975A5 (https=
JP2023502398A (ja
Inventor
クリスティーン・モレル・コクリ
ジョナソン・アンドリュー・クラフト
ウィリアム・トーマス・シモンズ・ザ・サード
Original Assignee
イミュノバント・サイエンシズ・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノバント・サイエンシズ・ゲーエムベーハー filed Critical イミュノバント・サイエンシズ・ゲーエムベーハー
Publication of JP2023502398A publication Critical patent/JP2023502398A/ja
Publication of JP2023502398A5 publication Critical patent/JP2023502398A5/ja
Publication of JPWO2021101975A5 publication Critical patent/JPWO2021101975A5/ja
Application granted granted Critical
Publication of JP7722991B2 publication Critical patent/JP7722991B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022529066A 2019-11-19 2020-11-18 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法 Active JP7722991B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962937395P 2019-11-19 2019-11-19
US62/937,395 2019-11-19
PCT/US2020/061028 WO2021101975A1 (en) 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies

Publications (4)

Publication Number Publication Date
JP2023502398A JP2023502398A (ja) 2023-01-24
JP2023502398A5 JP2023502398A5 (https=) 2023-11-15
JPWO2021101975A5 JPWO2021101975A5 (https=) 2023-11-15
JP7722991B2 true JP7722991B2 (ja) 2025-08-13

Family

ID=73854886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529066A Active JP7722991B2 (ja) 2019-11-19 2020-11-18 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法

Country Status (11)

Country Link
US (1) US20230049011A1 (https=)
EP (1) EP4061486A1 (https=)
JP (1) JP7722991B2 (https=)
KR (1) KR20220100880A (https=)
CN (1) CN114728180A (https=)
AU (1) AU2020387399A1 (https=)
CA (1) CA3157797A1 (https=)
IL (1) IL292889A (https=)
MX (1) MX2022005862A (https=)
TW (1) TW202132346A (https=)
WO (1) WO2021101975A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250136699A1 (en) * 2021-08-13 2025-05-01 Jiangsu Biojetay Biotechnology Co., Ltd. Antibodies specifically recognizing fcrn and uses thereof
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
US20260078188A1 (en) * 2022-09-06 2026-03-19 Immunovant Sciences Gmbh Methods of treating graves’ disease using anti-fcrn antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522043A (ja) 2014-04-30 2017-08-10 ハノル バイオファーマ カンパニーリミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． ＦｃＲｎ特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336825B2 (en) * 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
KR20250052465A (ko) * 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
ES2956662T3 (es) * 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
CA3032415A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2019160979A1 (en) * 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522043A (ja) 2014-04-30 2017-08-10 ハノル バイオファーマ カンパニーリミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． ＦｃＲｎ特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood，130 (Suppl_1)，2017年，3483, Abstract No. 101
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia (ENERGY)，ClinicalTrials.gov，NCT04119050 [オンライン］，2019年11月08日，[検索日 2024.09.23］，インターネット<URL:https://clinicaltrials.gov/study/NCT04119050?cond=NCT04119050&rank=1&tab=history&a=3#version-content-panel>

Also Published As

Publication number Publication date
IL292889A (en) 2022-07-01
US20230049011A1 (en) 2023-02-16
EP4061486A1 (en) 2022-09-28
CN114728180A (zh) 2022-07-08
WO2021101975A1 (en) 2021-05-27
JP2023502398A (ja) 2023-01-24
AU2020387399A1 (en) 2022-05-19
MX2022005862A (es) 2022-06-23
TW202132346A (zh) 2021-09-01
CA3157797A1 (en) 2021-05-27
KR20220100880A (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
JP7489978B2 (ja) 抗ＦｃＲｎ抗体を用いたグレーブス眼症の治療方法
AU2007238677B2 (en) Use of IL-I antibodies for treating ophthalmic disorders
EP3137504B1 (en) Antibody binding to fcrn for treating autoimmune diseases
JP7722991B2 (ja) 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法
KR20250084991A (ko) 항-FcRN 항체를 이용한 만성 염증성 탈수초성 다발성 신경병증의 치료 방법
US20260078188A1 (en) Methods of treating graves’ disease using anti-fcrn antibodies
HK40068854A (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
HK40058301B (zh) 使用抗fcrn抗体治疗格雷夫斯眼病的方法
HK40058301A (en) Methods of treating graves&#39; ophthalmopathy using anti-fcrn antibodies
HK40121539A (zh) 使用抗fcrn抗体治疗慢性炎性脱髓鞘性多发性神经病的方法
HK40124168A (zh) 使用抗fcrn抗体治疗格雷夫斯病的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250715

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250731

R150 Certificate of patent or registration of utility model

Ref document number: 7722991

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150